Agilent and Shimadzu to Exchange Chromatography Instrument Drivers
News May 29, 2013
Agilent Technologies Inc. and Shimadzu Corp. announce that they will exchange RapidControl.NET (RC.Net) instrument drivers. Shimadzu’s adoption and support of Agilent’s RC.Net driver standard strengthens RC.Net as an emerging open industry standard for instrument control across multiple data systems.
Through this exchange, Shimadzu LabSolutions and Agilent OpenLAB Chromatography Data Systems will control both manufacturers’ instruments, providing customers more freedom of choice in instrumentation for their laboratories, regardless of which CDS they use. In addition, customers can preserve their investment in workflow definition and supporting operating procedures.
“At Agilent, we are fully committed to bringing instrument control solutions for the most popular chromatography instruments into OpenLAB CDS,” said Bruce von Herrmann, general manager of Agilent Software and Informatics. “Our agreement with Shimadzu represents the continued cooperation of both companies. OpenLAB CDS customers will now be able to utilize the features and functions of their Shimadzu instrumentation on our newest CDS product.”
“At Shimadzu, we are dedicated to providing flexible instrumentation and software solutions for our customers,” said Masami Tomita, Shimadzu general manager of LC Business Unit, Life Science Business Department. “We are pleased to announce that Shimadzu instruments are now able to be controlled by Agilent OpenLAB CDS. Our collaboration will provide a more integrated solution for customers who require a single CDS product to provide seamless multi-vendor control of all instruments in their laboratory. This will allow any CDS which supports RC.Net to control our instruments. Shimadzu’s adoption and implementation of the RC.Net standard will also enable Agilent instruments to be controlled by Shimadzu LabSolutions CDS.”
The new Shimadzu RC.Net drivers will initially support Shimadzu’s Nexera and Prominence HPLC lines. These drivers will be made available on Agilent’s OpenLAB CDS later this month. Shimadzu’s LabSolutions CDS will gain the Agilent HPLC RC.Net drivers, supporting Agilent’s 1100, 1200, 1260 and 1290 series instruments. This integration is expected to occur in August.
For GCs, the new Shimadzu RC.Net drivers will initially support Shimadzu’s GC-2010/Plus and GC-2014 product lines in exchange for Agilent’s GC RC.Net drivers supporting Agilent 6890, 7820 and 7890 series instruments. The expected timing for completing this development is late 2013.
For more information about Shimadzu’s LabSolutions chromatography systems, visit www.shimadzu.com/an/data-net.
For more information about Agilent OpenLAB CDS, visit www.chem.agilent.com/en-US/Products-Services/Software-Informatics.
Honey Bee Gut Metabolome Reveals How They Cope With a Pollen Rich DietNews
The honey bee gut is colonized by specialized bacteria that help digest components of the floral pollen diet and produce molecules that likely promote bee health. Researchers studied the metabolome from the bee gut and have uncovered which bacterial species perform which specific digestive functions.
Novel Isotope Tracking Method Offers Hope for Threatened SpeciesNews
Locating even a single nest of the secretive goshawk required weeks of exploration. So scientists decided to conduct elemental analysis using strontium, which has naturally occurring isotopes found everywhere on Earth that travel the food chain from the soil to plants to herbivores and predators. Analysing prey remains enabled the researchers to determine where the birds of prey were hunting, findings that could help steer conservation efforts for goshawks and other vulnerable species.READ MORE
New Therapeutic Could Help in the Battle Against TBNews
In search of new antibiotics, researchers have developed a structural analogue of mycolic acid, the essential membrane building block. This drug blocks key enzymes used in mycomembrane biosynthesis, significantly increasing the effectiveness of conventional antibiotics. This could provide a novel approach for tuberculosis treatment.READ MORE